VIDEO: Low-dose pilocarpine eye drops for presbyopia show promising outcomes
Key takeaways:
- CSF-1 0.4% pilocarpine drops for presbyopia showed promising outcomes in phase 3 trials.
- The drops were well tolerated with minimal side effects and no compromise in distance vision.
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Marjan Farid, MD, presents the phase 3 data of CSF-1 0.4% pilocarpine solution from Orasis for the treatment of presbyopia.
The cumulative results of the NEAR 1 and NEAR 2 pivotal trials showed an increase of three or more lines of distance corrected near vision in a significant number of patients after instillation of the first daily drop, augmented effect after the second daily drop, and duration of effect of up to 8 hours after 15 days of treatment.
CSF-1 was well tolerated, side effects were minimal, transient and mild, and there was no compromise in distance vision.
“We know that presbyopia is ubiquitous. It really impacts quality of life, and it is very exciting to be able to present another possible solution for the treatment of presbyopia,” Farid said.
Collapse
Farid M, et al. CSF-1 (0.4% pilocarpine HCl ophthalmic solution) for the treatment of presbyopia: Near-1 and Near-2 phase 3 clinical trials. Presented at: American Society of Cataract and Refractive Surgery meeting; May 5-8, 2023; San Diego.
Read more about